GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lipidor AB (OSTO:LIPI) » Definitions » Debt-to-EBITDA

Lipidor AB (OSTO:LIPI) Debt-to-EBITDA : 0.00 (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Lipidor AB Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Lipidor AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was kr0.00 Mil. Lipidor AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was kr0.00 Mil. Lipidor AB's annualized EBITDA for the quarter that ended in Jun. 2024 was kr-19.70 Mil. Lipidor AB's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Lipidor AB's Debt-to-EBITDA or its related term are showing as below:

OSTO:LIPI' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.05   Med: -0.05   Max: -0.04
Current: -0.04

During the past 7 years, the highest Debt-to-EBITDA Ratio of Lipidor AB was -0.04. The lowest was -0.05. And the median was -0.05.

OSTO:LIPI's Debt-to-EBITDA is ranked worse than
100% of 656 companies
in the Drug Manufacturers industry
Industry Median: 1.67 vs OSTO:LIPI: -0.04

Lipidor AB Debt-to-EBITDA Historical Data

The historical data trend for Lipidor AB's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipidor AB Debt-to-EBITDA Chart

Lipidor AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial - - - - -0.05

Lipidor AB Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.11 -0.03 0.27 -

Competitive Comparison of Lipidor AB's Debt-to-EBITDA

For the Drug Manufacturers - General subindustry, Lipidor AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lipidor AB's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lipidor AB's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Lipidor AB's Debt-to-EBITDA falls into.



Lipidor AB Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Lipidor AB's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.525 + 0) / -10.62
=-0.05

Lipidor AB's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -19.704
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2024) EBITDA data.


Lipidor AB  (OSTO:LIPI) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Lipidor AB Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Lipidor AB's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Lipidor AB Business Description

Traded in Other Exchanges
N/A
Address
c/o Ekonomistubben AB, Box 55931, Stockholm, SWE, 102 16
Lipidor AB is a pharmaceutical development company with a pipeline of drug development projects in the preclinical and clinical phases. The company develops drugs for the treatment of skin diseases such as psoriasis, bacterial skin infections, and atopic dermatitis.

Lipidor AB Headlines

No Headlines